WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
www.gsk.com
GlaxoSmithKline RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category GlaxoSmithKline
Title
Published Date
GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China
15 June 2011
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)
13 June 2011
Millions of children in the world's poorest countries could receive vaccination against rotavirus diarrhoeal disease
09 June 2011
GSK forms partnership with three leading NGOs
25 May 2011
Pharmaceutical industry and university create Manchester Collaborative Centre for Inflammation Research
12 May 2011
GSK welcomes key agreement to support global preparedness against pandemic influenza
19 April 2011
GSK publishes payments for research, consulting and advising by US healthcare professionals
01 April 2011
GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction
28 March 2011
GSK supports recovery efforts to help those affected by the Japan earthquake
20 March 2011
GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson's disease
15 March 2011
Start
Prev
5
6
7
8
9
10
11
12
13
14
Next
End
Business & Industry
Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY®
Amgen successfully completes acquisition of Five Prime Therapeutics
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Research & Development
Differing immune responses discovered in asymptomatic cases vs those with severe COVID-19
Patients who are obese or overweight are at risk for a more severe course of COVID-19
New COVID-19 vaccine may offer broad protection from coronaviruses
SARS-CoV-2: New findings on the persistence of neutralizing antibodies
Massive fragment screen points way to new SARS-CoV-2 inhibitors
B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
COVID-19 causes 'unexpected' cellular response in the lungs
Conferences & Events
Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
CPhI Worldwide to return in 2021
Reuters Events' Cell & Gene Therapy USA
Total health: Build a better healthcare system
Don't fall for the 'next best action' trap
Locking down shape-shifting spike protein aids development of COVID-19 vaccine
COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
You are here:
Home
GlaxoSmithKline
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19